Conclusions Based on the results presented herein, it is suggested that TF-MISO has the potential to be a valid magnetic resonance hypoxia imaging reporter for both pre-clinical hypoxia studies and hypoxia directed clinical therapy.
INTRODUCTION
Hypoxia is a condition common to many diseases, particularly malignant tumors. Poor blood supply and/or an abnormal vascular architecture can decrease the tissue oxygen tension and render tumors more resistant to radiotherapy and many kinds of chemotherapy [1] . Recent studies aimed at understanding the molecular mechanisms underlying hypoxia have revealed its correlation with genetic instability, poor prognosis, tumor progression, and angiogenesis and have demonstrated how hypoxia is a widely heterogeneous problem [2] [3] [4] [5] [6] [7] [8] . In many cases tumors that appear identical by clinical and radiographic criteria can vary greatly in their extent of hypoxia. Therefore, measuring tumor hypoxia in vivo on an individual basis is not only important to further characterize lesions, but also essential for developing hypoxia-directed therapeutic approaches.
Several techniques have been suggested as diagnostic tools to detect and image hypoxia, both invasively and non-invasively. Some of these methods have undergone preclinical evaluation, although none have entered widespread clinical use [9] .
Among the non invasive hypoxia markers 2-nitroimidazoles represent a class of compounds that are known to be reduced intracellularly via several enzymatic pathways [10] . In the absence of an adequate oxygen supply, these compounds undergo reduction to reactive products that bind to cellular components [11] . By monitoring the in vivo uptake, tissue distribution and retention of these compounds, it is potentially possible to assess the presence of hypoxic tissue. Nitroimidazoles have been used in a wide variety of applications including immunohistochemical assays, fluorescence microscopy, positron emission tomography (PET) [12] [13] and nuclear magnetic resonance [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In the past Chapman et al have conducted a thorough biological characterization of several different nitroimidazole compounds [12] . Among the several compounds investigated they have identified a fluorinated 2-nitro-alpha-[(2,2,2-trifluoroethoxy)methyl]-imidazole-1-ethanol (TF-MISO), analog of the more well characterized fluoromisonidazole (MISO), with physiochemical properties suggestive of a good MR cellular hypoxia probe [26] . In this perspective the most relevant properties of TF-MISO as determined by Chapman et al are:
1) TF-MISO's octanol/water partition coefficient (p.c.) is larger than most other nitroimidazoles including MISO (p. c. of TF-MISO ~ 2.6 while p. c. of MISO ~0.43). A higher partition coefficient is associated with higher lipophilicity which is in turn connected to (i) higher affinity to tissues, (ii) higher affinity for metabolizing enzymes and transporter proteins, (iii) decreased solubility and thus (iv) more free drug available to target hypoxic tissues; 2) the in vitro nitroreduction binding rate of TF-MISO to EMT-6 hypoxic cells, which relates to the rate of adduct formation, is similar to those of MISO and therefore has been established as related to hypoxia levels in tissue and finally 3) measurements of 14 C activity recovered from tissue samples excised at different times after administration of labeled compound indicate that TF-MISO is characterized by a plasma half life of approximately 23 minutes and was shown to be rapidly cleared from most tissues such as blood, muscle, brain, spleen and kidney (after 2 hours there is a six fold decrease of activity) and was retained for longer times in tissues which exhibit a certain degree of hypoxia such as tumor and liver (at 6 hours and later these tissues exhibit the highest activity, 3 fold higher than other normal tissue) [26] .
Based on the above considerations and results reported we investigated TF-MISO with the aim of : (1) examining the in vivo kinetics of TF-MISO by 19 F magnetic resonance spectroscopy (MRS) in solid tumors with known levels of hypoxia, (2) demonstrating that the signal is visible for extended periods of time and therefore associated with intracellular bound and reduced adducts of TF-MISO and (3) investigating the feasibility of imaging the spatial distribution of TF-MISO inside the tumor within a reasonable time frame following the administration of non-toxic doses.
MATERIALS AND METHODS

TF-MISO
TF-MISO was obtained from SynChem OHG Laboratories (CAS Number 21787-91-7).
The chemical structure is shown in Fig 2- From the cell number (determined for each individual sample after collection of the supernatant) and the decrease in the amount of TF-MISO in the medium, the cellular uptake of TF-MISO was calculated and expressed as nmol/10 5 cells.
Cell lines and animal models
All animal studies were done according to institutionally approved protocols. For studies with the MCa tumor model, the tumors were removed aseptically from tumor-bearing animals by previously described methods [28] . Briefly, a single-cell suspension was prepared from a solid tumor by teasing and abrasion against a stainless steel mesh immersed in minimal essential medium (MEM) containing 2% heparin. Cell suspensions were additionally disrupted by aspiration through an 18-Gauge needle and the final suspension was agitated constantly by a magnetic spin bar. A tumor inoculum of 0.025 to 0.04 ml (~ 10 5 cells) was injected subcutaneously into the dorsum of the foot of male (2) based on results of a recent study [29] which showed how tissue partial oxygen pressure (pO 2 ) measured using polarographic oxygen electrodes (OxyLite System) remains stable in animals anesthetized with isoflurane/air whereas it fluctuates in animals anesthetized with other types of anesthetic agents such as ketamine combined with xylazine, phenoparbital, fentanyl, citrate/fluanisone and midazolam. The leg with the tumor was allowed to protrude through a hole in the syringe and the tumor was carefully placed inside a home-built three-turn solenoid coil. Care was taken not to stretch or overtly constrain the mouse extremity in order to eliminate the risk of investigator induced alterations in blood supply. In the case of flank tumors, care was taken not to stretch or damage the protruding tumor which was placed inside the coil.
Mice were scanned for a maximum duration of five hours. Several mice were restudied after being removed from the holder and allowed to rest for 2-3 hours before being restudied.
In all cases hydration of the mice was provided prior and after each imaging session by subcutaneous injection of sterile saline solution (~0.1-0.2 ml). In order to preserve the core temperature of the mouse throughout the experiments, thus preventing hypothermia and associated effects, temperature controlled warm air was blown softly on the animal (carefully padded and shielded in the holder) and a rectal temperature sensor was used to assess body temperature and provide feedback to the animal monitoring and temperature control system (Model 1025 from SA Instruments, Inc., Stony Brook, NY). Using this system the temperature was maintained at ~ 37 °C, the normal rectum physiological temperature. Respiration was monitored via a pressure pillow placed under the mouse's body also connected to the animal monitoring system. When euthanasia of the animal during the experiment was deemed necessary, an overdose of inhaled anesthetic was used (isofluorane) as recommended by animal protocols and death was ascertained by cessation of respiratory signal.
A glass sphere (18 µl) filled with sodium fluoride (NaF) 75 mM was used as an external reference for 19 F MRS quantitation purposes. Gadopentetate dimeglumine (Magnevist®)
15 mM was added to the reference solution in order to enhance relaxation effects (nuclear spin-lattice relaxation time T 1 < 0.3 s) and to enable a faster acquisition of the reference signal (i.e. shorter repetition times (TR)). MHz to 300 MHz. 1 H anatomical imaging was done using the Paravision PVM Method RARE (Rapid Acquisition with Relaxation Enhancement). The following parameters were used: effective echo time TE ~ 40 ms (RARE factor=8); TR=3000 ms, number of averages=8, matrix size 256×256 with a field of view of 2.5 cm × 2.5 cm (spatial resolution ~100 µm). Slice selective two dimensional 19 F CSI was implemented using the Paravision PVM method CSI2D using a Hanning function to perform a k-space weighted acquisition [31] [32] . This weighting scheme was employed to improve the shape of the spatial response function and the signal to noise ratio of the in vivo data. The following parameters were used for the CSI acquisition: a single 60º pulse with TR= 0.8 s; the same geometry as for anatomical imaging was used, i.e. a field of view of 2.5 cm ×2.5 cm and 3 mm slice thickness. The effective number of voxels was chosen to be 8×8
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yielding an effective voxel size of ~ 3×3×3 mm 3 . After applying the Hanning filtering and spatial zero filling up to 16×16 we obtain a digital resolution of ~1.5×1.5 mm 2 . The number of total acquisitions was different for each experiment, depending on the dose of TF-MISO and the resulting averaging requirements (~ 26 minutes at 200mg/kg and ~ 60 minutes at 75 mg/kg). Chemical shift data processing was performed using the CSI Visualization Tool included in the ParaVision software. The relative spectral intensity of TF-MISO over the defined interval was calculated and color encoded for each CSI voxel.
Care was taken when analyzing the data to discriminate between the TF-MISO and the isofluorane peak (also visible in the CSI data). The resulting TF-MISO map was then overlaid on top of the anatomical reference image. After spatial zero filling and Fourier transformation, resizing of the CSI voxels was also performed via quadratic interpolation using the resolution of the morphological image (~100µm). The intensity of the metabolite map was adjusted according to chosen settings with the purpose of overlaying on the morphological reference only those pixels which have intensities greater than a chosen threshold. The criterion for choosing the threshold values was to obtain a color TF-MISO map with no signal in those voxels which did not include the tumor, i.e. we set the threshold values in order to completely remove background noise. For the case of the 200 mg/kg data the signal to noise ratio (S/N) from the voxels included in the metabolite map was greater than 2 while for the case of the 75 mg/kg the S/N was greater than 1.5.
No additional software post processing of the images or of the metabolite map was involved in the co-registration procedure.
Experimental Graphs and Data Processing
All data were plotted and processed using ORIGIN 7.0 (OriginLab Corporation Northampton, MA). Curve fitting was performed using the non-linear least squares fitting (NLSF) capability of the software. Mean quantities are reported with experimental error
given by the standard deviation of the data or using standard propagation of error theory when using equations with experimentally derived quantities [33] . tissue at different times after a dose of 75 mg/kg (n=11). Although the signal in the tumor was already detectable after 15 minutes we decided to use a temporal resolution of 45 minutes to obtain a kinetic profile with less scatter (see stacked plot in Fig. 4b ). The 19 F MR signal was followed in some cases for up to 10-12 hours (data not shownanimals were removed from the magnet at various times to limit a single study to < 5 hours), after which the intensity of the resonance decreased in some cases and disappeared in others. One can observe an initial rapid decrease during the first 100 minutes (the concentration at 60 minutes is 0.27 ± 0.17 mM, ~ 73 µg/ml), followed by a slow decreasing trend which appears to be nearly constant in the range 100-300 minutes, to a concentration of 0.14 ± 0.10 mM (~ 40 µg/ml).
RESULTS
In-vitro uptake of TF-MISO as a function of concentration and oxygenation status
To analyze the effect of tumor volume on TF-MISO retention, we studied both the MCa foot tumors and a subcutaneous tumor model R3327-AT implanted on the thigh. The data (MCa and R3327-AT) revealed a correlation between the tumor size and the tumor tissue retention index (see Fig 5(a) ) defined by Aboagye et al. [18] as the ratio of TF-MISO concentration at six hour, n(6 hour), to the TF-MISO concentration at one hour, n(1 hour),
It is interesting to note that while in general the spectra obtained at early times ( 
DISCUSSION
The role of hypoxia in the development and progression of cancer and its importance in the response to therapy is well studied. The advantages of using 19 F magnetic resonance spectroscopy and imaging of fluorinated compounds to trace hypoxia in vivo can be associated with the following reasons: (1) 19 F is an NMR "friendly" nucleus (i.e. 100%
natural abundance, high NMR sensitivity and large γ value) and therefore is an efficient reporter molecule for in vivo studies; (2) the technique is intrinsically non-invasive; (3) there is no radioactivity involved and therefore the compounds are inherently stable with a long shelf life allowing studies at later time points post injection when the tumor/blood background is diminished; (4) well [18, 19] . This molecule was rationally designed to measure hypoxia specifically by magnetic resonance and is currently undergoing Phase 1 clinical trials [38] . While the preliminary data with this agent have been promising, a recent study showed no 19 F MRS in vivo signal was detected after injection of SR4554 in mice bearing wild type mutated gliomas with a well known hypoxic fraction [39] . This suggests the need to continue exploring other agents with slightly different characteristics (such as lipophilicity, protein binding or plasma clearance) in order to optimize hypoxia detection via MRS in a broad range of tumors. For these reasons and based on previous work by Chapman et al., [26] we selected TF-MISO for this preliminary 19 F MRS and CSI in vivo study aimed at establishing its potential as an MR reporter of cellular hypoxia in solid tumors.
Our focus has mainly been concentrated on characterizing the in vivo kinetics of TF-MISO by 19 F MRS and on investigating the possibility of imaging the spatial distribution of TF-MISO by CSI. A major issue when addressing the utility of 19 F MRS as a hypoxia marker is the nature of the adducts formed by the fluorinated bioreductive probes [40] .
Previously reported data [26] suggests that that TF-MISO adducts at latter times are present at significantly higher amounts in hypoxic (liver and tumor) versus non hypoxic tissues (blood, muscle, spleen, kidneys). Regarding the possibility of catabolism of TF-MISO which could potentially affect its role as a valid hypoxia reporter, we note that the most likely other possible metabolism of TF-MISO could be the cleavage of the trifluoroethoxy group, which in turn would be metabolized to trifluoroacetic acid and rapidly excreted (minutes after injection ) through the kidneys [41] . As the scanning takes place at least 30 minutes after injection, the only impact this would have would be a lower target tissue uptake of TF-MISO. Finally our HPLC studies have shown that TF-MISO is indeed stable both in cells and plasma (data not reported).
For these reasons we attempted to address the question of the source of the in vivo rapidly, but still on a time scale much slower than the parent compound [40] . Using a phenomenological biexponential model to describe the pharmacokinetic data we were able to estimate the tumor retention index, (54 ± 8 %) for the MCa tumor. The result is highly consistent with the data reported by Chapman et al [26] and with those reported by Mahmood et al [28] . The connection between the stage of development of the tumor (tumor size) and its degree of hypoxia is also important and will need to be addressed in order to assess the possibility of late time retention of the signal arising from diffused TF-MISO within necrotic areas. However we note that in our case one can exclude the contribution to the signal of TF-MISO trapped in large necrotic areas by pointing out how such areas would be easily visible in the T 2 -weighted tumor image. This is similarly an important issue also when addressing the observation of nitroimidazoles using PET and pimonidazole staining [43] .
After establishing the visibility and source of the 19 F signal, this study also demonstrated that real time imaging of the tumor distribution of TF-MISO is possible using 2D slice selective CSI with a k-space filtering acquisition modality, which greatly improves the signal to noise ratio and thus the ability to visualize changes in TF-MISO distribution.
To this end it is noted that TF-MISO is a good candidate for real time imaging studies of hypoxia since the 19 [44, 45] .
The feasibility of performing these studies clinically was also considered. If one considers, for example, lymph nodes from head and neck tumors where the issue of tumor hypoxia is under active investigation, the superficial location of these nodes, would make it relatively easy to study with high MR sensitivity. Since hypoxia is a microscopic variable, all non-invasive imaging will be imperfect since the ideal goal is to map hypoxia at a resolution of the size of the cell. However, in non-invasive imaging studies, voxel) would appear to be feasible in a clinical setting for studying superficial nodes.
One could also consider a 34 minute acquisition as has been done with 31 P MRSI tumor studies [46] [47] [48] .
A major benefit to the study TF-MISO by 19 F NMR, is that it can be labeled with 18 F also. This will allow direct comparisons between PET and NMR imaging of the same agent. Although PET-MR scanners for clinical use are under development [49] , there are none currently being used in the clinics and therefore one would still need to perform image coregistration for clinical studies, however, one would be assured that the origin of the signal would be identical for both modalities. In preclinical studies wherein one can do combined PET and MR studies either on the same instrument or on the same platform and simultaneously [50] the issue of image registration would be simplified providing assurance that both modalities were observing the same biological phenomenon.
Further investigation and validation of TF-MISO which was out of the scope of this initial study, will require the following steps: (1) we suggest that the compound represents a valid candidate as a hypoxia reporter which could be used both for basic hypoxia oriented investigations and potentially as a clinical diagnostic tool for hypoxia directed therapy. 
